Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2025-08-14 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
薪酬与考核委员会议事规则（2025年8月修订）
Remuneration Information Classification · 95% confidence The document is titled '薪酬与考核委员会议事规则' which translates to 'Rules of Procedure for the Remuneration and Assessment Committee'. It details the composition, responsibilities, meeting procedures, and duties of the Remuneration and Assessment Committee of the company. The content focuses on governance aspects related to executive compensation and performance evaluation, including committee structure, meeting protocols, and confidentiality obligations. There is no financial data, earnings information, or report publication mentioned. The document is a governance-related internal rules document concerning remuneration and assessment committee operations, which fits the definition of Remuneration Information filings. Therefore, the appropriate classification is 'DEF 14A' (Remuneration Information). The document length and detail support a high confidence in this classification.
2025-08-14 Chinese
关于全资子公司收到药品注册受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving a drug registration acceptance notice from the National Medical Products Administration. It details the drug registration application, product information, and risk warnings. The document is short (853 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report data. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-05 Chinese
关于在下属子公司之间调剂担保额度及为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about adjustments and progress related to guarantee limits and guarantees provided between its subsidiaries. It includes specifics about guarantee amounts, contracts with banks, financial data of the subsidiaries, and board and shareholder meeting approvals. The document is not a full financial report, audit report, or earnings release. It is not a call transcript, nor a merger or acquisition filing. It is a regulatory announcement about financing guarantees and related approvals, including references to board and shareholder meetings but not the meeting materials themselves. The document is lengthy (8985 characters) and contains substantive information about guarantees and financing arrangements, but it is primarily an announcement of guarantee arrangements and progress rather than a financial report or management discussion. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to updates on company financing activities and guarantee arrangements.
2025-07-17 Chinese
关于全资子公司收到药品注册受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving a drug registration acceptance notice from the National Medical Products Administration. It details the drug registration application, product information, and risk warnings. The document is short (1017 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-07-17 Chinese
关于全资子公司获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving approval for a drug clinical trial from the national drug regulatory authority. It details the drug name, approval specifics, and risk warnings related to the clinical trial stage. The document is short (1031 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report, management change, or shareholder meeting material. It does not contain financial data or results, nor is it a report publication notice. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-25 Chinese
关于全资子公司获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving approval for a drug clinical trial from the National Medical Products Administration (国家药品监督管理局). It details the drug name, clinical trial approval, regulatory compliance, and risk warnings related to the clinical trial process. The document is short (1130 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of a regulatory approval event related to drug development, not a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about a material event affecting the company, but not a financial report or governance document.
2025-06-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.